By Meredith Melnick Thursday, September 15, 2011
Like Kleenex and Band-Aid, Botox® is a brand name that’s become indistinguishable from the product. But in a new randomized study, Botox®’s newer competitor, Dysport®, appeared to have the edge in smoothing wrinkles.
Botox® (onabotulinumtoxinA) was approved by the Food and Drug Administration (FDA) to treat frown lines — those pesky wrinkles between the eyebrows — in 2002. In 2009, a competitor, Dysport® (abobotulinumtoxinA) was approved for the same use.
Both drugs have also been approved for other cosmetic and medical uses, and doctors administer them widely to smooth wrinkles even in areas they haven’t been specifically approved to treat, namely around the outer corner of the eyes.
http://aafe.thinkagencystaging.com/wp-admin/post-new.php
By Arianna Bankovich, RN Introduction: Botox, derived from the bacterium Clostridium botulinum, has long been renowned for its cosmetic applications in reducing wrinkles and fine
By Crystal Wilson, CNP In the dynamic landscape of healthcare, career trajectories often take unexpected turns. One noticeable trend in recent years is the increasing
By Katie Barrer, RDH Who better suited to treat their patients for bruxism than dental hygienists? Two states allow RDHs to administer Botox for